In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taisho Pharmaceutical Co. Ltd.

www.taisho.co.jp

Latest From Taisho Pharmaceutical Co. Ltd.

Japan's Taisho Suffers Declines At Home And Abroad As It Ends Disappointing Year

With sales falling across the board in 2018, Taisho is counting on acquisitions overseas and new organic growth initiatives at home to turn the tide.
Sales & Earnings OTC Drugs

In Consumers' Self-Care Drive, OTC Firms See Platform For Boosting Industry Trust

Influencing consumers with facts about health care topics frequently littered with inaccurate advice from non-expert social media sources requires having trust, say consumer health business executives from Bayer, J&J, Sanofi and Taisho Pharmaceutical at the Consumer Healthcare Products Association executive conference. "From a trust perspective, I think that health care is a deeply personal and emotional issue. ... it is definitely important to be fact-based," said Katie Devine, J&J's consumer self-care business global president.

OTC Drugs Prescription To Otc Switch

Japan's Taisho Banking On European Entry to Reverse Declining Sales

With sales declining at home and overseas, Taisho is banking on its push into Europe with the acquisition of UPSA from Bristol-Myers Squibb to reverse the fortunes of its consumer health-focused Self-Medication business.
Business Strategies Sales & Earnings

Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis

As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period… 
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register